Cancer name Head and Neck Cancer
Cancer Type HNSC
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment Cetuximab
Drugstatus Approved
Drugbank ID DB00002
Checkpoints NA
Signature Type Protein
Signature Bcl-2
Official Symbol BCL2
Mode of action PROT_R_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description Urelumab alone enhances Bcl-xL level in both CD56low NKand CD56bright NK.Higher levels of Bcl-xL were observed in NK cells activated by cetuximab alone. Interestingly, the combination of urelumab and cetuximab further increased the levels of Bcl-xL on NK cells. Similarly, urelumab and cetuximab alone enhanced Bcl-2 expression in CD56dim, and CD56bright NK cells. Again, the combination of urelumab and cetuximab significantly increased Bcl-2 expression on both NK cell subsets, and addition of urelumab enhanced viability of NK cells
PMID 27496866
Title CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer